|
|||||
|
|
Phase 3, open‐label,randomized study of the pharmacokinetics,efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A) |
|
| Authors: | K. Callis Duffin J. Bagel M. Bukhalo I.J. Mercado Clement S.L. Choi F. Zhao A. Gill B. Pangallo C. Shuler L. Mallbris K. Jackson |
| Affiliation: | 1. Department of Dermatology, University of Utah, Salt Lake City, UT, USA;2. Psoriasis Treatment Center of Central New Jersey, Windsor, NJ, USA;3. Altman Dermatology Associates, Arlington Heights, IL, USA;4. Lilly‐NUS Centre for Clinical Pharmacology, Singapore City, Singapore;5. Eli Lilly and Company, Indianapolis, IN, USA;6. Eli Lilly and Company, Windlesham, UK |
| Abstract: | |
| Keywords: | |